drTarget portfolio target-disease associations for gastrointestinal diseases DrTarget’s AI-Powered Indication Expansion for Gastrointestinal Diseases

AI-Driven Drug Discovery for Gastrointestinal Diseases

DrTarget harnesses advanced AI and bioinformatics to uncover novel disease-target associations for gastrointestinal (GI) disorders. Using machine learning and pathway analysis, we identify new therapeutic opportunities for:

✔ Inflammatory Bowel Disease (IBD) – Discovering novel targets for Crohn’s disease and ulcerative colitis.
✔ Liver Diseases – Identifying compounds for NAFLD, NASH, and liver fibrosis.
✔ Gastrointestinal Cancers – Enhancing drug discovery for colorectal, gastric, and pancreatic cancers.
✔ Microbiome-Linked Disorders – Exploring AI-based insights into gut microbiota interactions.

Target-disease associations for gastrointestinal diseases.

Check best scored target-disease associations in table:

entries per page

Search:

BioAssay Name	program	diseaseName	assayType	associationScore	numberOfEvidences	testedCompounds	activeCompounds

BioAssay Name	program	diseaseName	assayType	associationScore	numberOfEvidences	testedCompounds	activeCompounds
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Diarrhea	targetBased	0.66	134	335239	695
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Diarrhea	targetBased	0.66	134	335239	991
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	gastrointestinal disease	targetBased	0.65	44	359207	4555
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	gastrointestinal disease	targetBased	0.65	44	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	gastrointestinal disease	targetBased	0.65	44	359207	316
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	gastrointestinal disease	targetBased	0.65	44	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	gastrointestinal disease	targetBased	0.65	44	359207	1189
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal obstruction	targetBased	0.63	37	335239	695
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal obstruction	targetBased	0.63	37	335239	991
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastrointestinal disease	targetBased	0.63	108	336308	6862

Showing 1 to 10 of 1,463 entries

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

entries per page

Search:

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	anus disease	DILTIAZEM	targetBased	2	Not yet recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04887818	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	PROPRANOLOL	targetBased	4	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT02740166	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	PROPRANOLOL	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT01134692	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	dyspepsia	BUSPIRONE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03444831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	dyspepsia	BUSPIRONE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03444831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dysphagia	BUSPIRONE	targetBased	4	Recruiting	06/07/2021	https://clinicaltrials.gov/study/NCT05629325	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dysphagia	BUSPIRONE	targetBased	4	Recruiting	06/07/2021	https://clinicaltrials.gov/study/NCT05629325	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastroparesis	BUSPIRONE	targetBased	2	Completed	27/08/2019	https://clinicaltrials.gov/study/NCT03587142	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastroparesis	BUSPIRONE	targetBased	2	Completed	27/08/2019	https://clinicaltrials.gov/study/NCT03587142	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution

Showing 1 to 10 of 1,155 entries

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.